{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:51:42Z","timestamp":1790635902599,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009318","name":"Helmholtz Association","doi-asserted-by":"publisher","award":["HVF0079"],"award-info":[{"award-number":["HVF0079"]}],"id":[{"id":"10.13039\/501100009318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Quantification of Amyloid beta (A\u03b2) oligomers in plasma enables early diagnosis of Alzheimer\u2019s Disease (AD) and improves our understanding of underlying pathologies. However, quantification necessitates an extremely sensitive and selective technology because of very low A\u03b2 oligomer concentrations and possible interference from matrix components.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this report, we developed and validated a surface-based fluorescence distribution analysis (sFIDA) assay for quantification of A\u03b2 oligomers in plasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The blood-based sFIDA assay delivers a sensitivity of 1.8 fM, an inter- and intra-assay variation below 20% for oligomer calibration standards and no interference with matrix components. Quantification of A\u03b2 oligomers in 359 plasma samples from the DELCODE cohort reveals lower oligomer concentrations in subjective cognitive decline and AD patients than healthy Control participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Correlation analysis between CSF and plasma oligomer concentrations indicates an impaired clearance of A\u03b2 oligomers that is dependent on the\n                      <jats:italic>ApoE<\/jats:italic>\n                      \u03b54 status.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-024-00690-w","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T07:00:38Z","timestamp":1733814038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Blood-based quantification of A\u03b2 oligomers indicates impaired clearance from brain in ApoE \u03b54 positive subjects"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-9224","authenticated-orcid":false,"given":"Lara","family":"Bl\u00f6meke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-0684","authenticated-orcid":false,"given":"Fabian","family":"Rehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-3675","authenticated-orcid":false,"given":"Marlene","family":"Pils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7413-7646","authenticated-orcid":false,"given":"Victoria","family":"Kraemer-Schulien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneliese","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7390","authenticated-orcid":false,"given":"Janine","family":"Kutzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7191-8455","authenticated-orcid":false,"given":"Tuyen","family":"Bujnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2141-8671","authenticated-orcid":false,"given":"Silka D.","family":"Freiesleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5822-1744","authenticated-orcid":false,"given":"Luisa-Sophie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Preis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike J.","family":"Spruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawek","family":"Altenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-8700","authenticated-orcid":false,"given":"Anja","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Fliessbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-5330","authenticated-orcid":false,"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-9594","authenticated-orcid":false,"given":"Niels","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Rostamzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"D\u00fczel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzel","family":"Glanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2014-4098","authenticated-orcid":false,"given":"Enise I.","family":"Incesoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Janowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ewers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris-Stephan","family":"Rauchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kilimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Laske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias H.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Spottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4996-1630","authenticated-orcid":false,"given":"Michael T.","family":"Heneka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-7516","authenticated-orcid":false,"given":"Frederic","family":"Brosseron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2589-6440","authenticated-orcid":false,"given":"Michael","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Roeske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4991-763X","authenticated-orcid":false,"given":"Alfredo","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bannach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-7366","authenticated-orcid":false,"given":"Dieter","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"690_CR1","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement (N Y 8, e12295 (2022). ."},{"key":"690_CR2","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"EN Cline","year":"2018","unstructured":"Cline, E. N., Bicca, M. A., Viola, K. L. & Klein, W. L. The Amyloid-\u03b2 Oligomer Hypothesis: Beginning of the Third Decade. J Alzheimers Dis 64, S567\u2013s610 (2018).","journal-title":"J Alzheimers Dis"},{"key":"690_CR3","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease. Molecular Psychiatry 26, 5481\u20135503 (2021).","journal-title":"Molecular Psychiatry"},{"key":"690_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00702-017-1820-x","volume":"125","author":"B Mroczko","year":"2018","unstructured":"Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J. & Lewczuk, P. Amyloid beta oligomers (AbetaOs) in Alzheimer\u2019s disease. J Neural Transm (Vienna) 125, 177\u2013191 (2018).","journal-title":"J Neural Transm (Vienna)"},{"key":"690_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/2045-8118-11-26","volume":"11","author":"SB Hladky","year":"2014","unstructured":"Hladky, S. B. & Barrand, M. A. Mechanisms of fluid movement into, through and out of the brain: evaluation of the evidence. Fluids Barriers CNS 11, 26 (2014).","journal-title":"Fluids Barriers CNS"},{"key":"690_CR6","doi-asserted-by":"publisher","first-page":"e66381","DOI":"10.1371\/journal.pone.0066381","volume":"8","author":"M Holtta","year":"2013","unstructured":"Holtta, M. et al. Evaluating amyloid-beta oligomers in cerebrospinal fluid as a biomarker for Alzheimer\u2019s disease. PLoS One 8, e66381 (2013).","journal-title":"PLoS One"},{"key":"690_CR7","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage, M. J. et al. A sensitive abeta oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J Neurosci 34, 2884\u20132897 (2014).","journal-title":"J Neurosci"},{"key":"690_CR8","doi-asserted-by":"publisher","first-page":"e67898","DOI":"10.1371\/journal.pone.0067898","volume":"8","author":"AZ Herskovits","year":"2013","unstructured":"Herskovits, A. Z., Locascio, J. J., Peskind, E. R., Li, G. & Hyman, B. T. A Luminex assay detects amyloid beta oligomers in Alzheimer\u2019s disease cerebrospinal fluid. PLoS One 8, e67898 (2013).","journal-title":"PLoS One"},{"key":"690_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3233\/JAD-122047","volume":"34","author":"L Wang-Dietrich","year":"2013","unstructured":"Wang-Dietrich, L. et al. The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer\u2019s disease. J Alzheimers Dis 34, 985\u2013994 (2013).","journal-title":"J Alzheimers Dis"},{"key":"690_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12640-018-9895-1","volume":"34","author":"SH Xin","year":"2018","unstructured":"Xin, S. H., Tan, L., Cao, X., Yu, J. T. & Tan, L. Clearance of Amyloid Beta and Tau in Alzheimer\u2019s Disease: from Mechanisms to Therapy. Neurotox Res 34, 733\u2013748 (2018).","journal-title":"Neurotox Res"},{"key":"690_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrneurol.2017.111","volume":"13","author":"J Wang","year":"2017","unstructured":"Wang, J., Gu, B. J., Masters, C. L. & Wang, Y. J. A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain. Nat Rev Neurol 13, 612\u2013623 (2017).","journal-title":"Nat Rev Neurol"},{"key":"690_CR12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/alz.12457","volume":"18","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. An ultra-sensitive immunoassay detects and quantifies soluble A\u03b2 oligomers in human plasma. Alzheimers Dement 18, 1186\u20131202 (2022).","journal-title":"Alzheimers Dement"},{"key":"690_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/archneurol.2008.565","volume":"66","author":"W Xia","year":"2009","unstructured":"Xia, W. et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66, 190\u2013199 (2009).","journal-title":"Arch Neurol"},{"key":"690_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12782","volume":"48","author":"C Kurz","year":"2022","unstructured":"Kurz, C., Walker, L., Rauchmann, B. S. & Perneczky, R. Dysfunction of the blood-brain barrier in Alzheimer\u2019s disease: Evidence from human studies. Neuropathol Appl Neurobiol 48, e12782 (2022).","journal-title":"Neuropathol Appl Neurobiol"},{"key":"690_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-017-0310-6","volume":"9","author":"SSA An","year":"2017","unstructured":"An, S. S. A. et al. Dynamic changes of oligomeric amyloid \u03b2 levels in plasma induced by spiked synthetic A\u03b2(42). Alzheimers Res Ther 9, 86 (2017).","journal-title":"Alzheimers Res Ther"},{"key":"690_CR16","volume":"2022","author":"JC Dominguez","year":"2022","unstructured":"Dominguez, J. C. et al. Multimer Detection System-Oligomerized Amyloid Beta (MDS-OA\u03b2): A Plasma-Based Biomarker Differentiates Alzheimer\u2019s Disease from Other Etiologies of Dementia. Int J Alzheimers Dis 2022, 9960832 (2022).","journal-title":"Int J Alzheimers Dis"},{"key":"690_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JAD-2008-14201","volume":"14","author":"AN Santos","year":"2008","unstructured":"Santos, A. N., Simm, A., Holthoff, V. & Boehm, G. A method for the detection of amyloid-beta1-40, amyloid-beta1-42 and amyloid-beta oligomers in blood using magnetic beads in combination with Flow cytometry and its application in the diagnostics of Alzheimer\u2019s disease. J Alzheimers Dis 14, 127\u2013131 (2008).","journal-title":"J Alzheimers Dis"},{"key":"690_CR18","doi-asserted-by":"publisher","unstructured":"Huang, Y. R. & Liu, R. T. The Toxicity and Polymorphism of \u03b2-Amyloid Oligomers. Int J Mol Sci 21, https:\/\/doi.org\/10.3390\/ijms21124477 (2020).","DOI":"10.3390\/ijms21124477"},{"key":"690_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jmb.2012.01.006","volume":"421","author":"M F\u00e4ndrich","year":"2012","unstructured":"F\u00e4ndrich, M. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. J Mol Biol 421, 427\u2013440 (2012).","journal-title":"J Mol Biol"},{"key":"690_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-019-0535-7","volume":"11","author":"X Meng","year":"2019","unstructured":"Meng, X. et al. Association between increased levels of amyloid-\u03b2 oligomers in plasma and episodic memory loss in Alzheimer\u2019s disease. Alzheimers Res Ther 11, 89 (2019).","journal-title":"Alzheimers Res Ther"},{"key":"690_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-017-0324-0","volume":"9","author":"MJ Wang","year":"2017","unstructured":"Wang, M. J. et al. Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease. Alzheimers Res Ther 9, 98 (2017).","journal-title":"Alzheimers Res Ther"},{"key":"690_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0299-y","volume":"51","author":"JC Lee","year":"2019","unstructured":"Lee, J. C., Kim, S. J., Hong, S. & Kim, Y. Diagnosis of Alzheimer\u2019s disease utilizing amyloid and tau as fluid biomarkers. Experimental & Molecular Medicine 51, 1\u201310 (2019).","journal-title":"Experimental & Molecular Medicine"},{"key":"690_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13195-021-00873-w","volume":"13","author":"R Babapour Mofrad","year":"2021","unstructured":"Babapour Mofrad, R. et al. Plasma amyloid-\u03b2 oligomerization assay as a pre-screening test for amyloid status. Alzheimers Res Ther 13, 133 (2021).","journal-title":"Alzheimers Res Ther"},{"key":"690_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.bbrc.2012.06.017","volume":"423","author":"L Zhou","year":"2012","unstructured":"Zhou, L. et al. Plasma amyloid-\u03b2 oligomers level is a biomarker for Alzheimer\u2019s disease diagnosis. Biochem Biophys Res Commun 423, 697\u2013702 (2012).","journal-title":"Biochem Biophys Res Commun"},{"key":"690_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213157119","volume":"119","author":"D Shea","year":"2022","unstructured":"Shea, D. et al. SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers. Proc Natl Acad Sci USA 119, e2213157119 (2022).","journal-title":"Proc Natl Acad Sci USA"},{"key":"690_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/1873-3468.12983","volume":"592","author":"A Kulawik","year":"2018","unstructured":"Kulawik, A., Heise, H., Zafiu, C., Willbold, D. & Bannach, O. Advancements of the sFIDA method for oligomer-based diagnostics of neurodegenerative diseases. FEBS Lett 592, 516\u2013534 (2018).","journal-title":"FEBS Lett"},{"key":"690_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cca.2017.01.010","volume":"466","author":"Y Herrmann","year":"2017","unstructured":"Herrmann, Y. et al. Nanoparticle standards for immuno-based quantitation of alpha-synuclein oligomers in diagnostics of Parkinson\u2019s disease and other synucleinopathies. Clin Chim Acta 466, 152\u2013159 (2017).","journal-title":"Clin Chim Acta"},{"key":"690_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/JAD-160253","volume":"54","author":"M H\u00fclsemann","year":"2016","unstructured":"H\u00fclsemann, M. et al. Biofunctionalized Silica Nanoparticles: Standards in Amyloid-beta Oligomer-Based Diagnosis of Alzheimer\u2019s Disease. J Alzheimers Dis 54, 79\u201388 (2016).","journal-title":"J Alzheimers Dis"},{"key":"690_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41531-022-00330-x","volume":"8","author":"L Bloemeke","year":"2022","unstructured":"Bloemeke, L. et al. Quantitative detection of alpha-Synuclein and Tau oligomers and other aggregates by digital single particle counting. NPJ Parkinsons Dis 8, 68 (2022).","journal-title":"NPJ Parkinsons Dis"},{"key":"690_CR30","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3233\/JAD-2010-100609","volume":"21","author":"D Sehlin","year":"2010","unstructured":"Sehlin, D. et al. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimers Dis 21, 1295\u20131301 (2010).","journal-title":"J Alzheimers Dis"},{"key":"690_CR31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41570-021-00254-9","volume":"5","author":"K Kulenkampff","year":"2021","unstructured":"Kulenkampff, K., Wolf Perez, A.-M., Sormanni, P., Habchi, J. & Vendruscolo, M. Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nature Reviews Chemistry 5, 277\u2013294 (2021).","journal-title":"Nature Reviews Chemistry"},{"key":"690_CR32","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/diagnostics13101702","volume":"13","author":"M Pils","year":"2023","unstructured":"Pils, M. et al. Development and Implementation of an Internal Quality Control Sample to Standardize Oligomer-Based Diagnostics of Alzheimer\u2019s Disease. Diagnostics 13, 1702 (2023).","journal-title":"Diagnostics"},{"key":"690_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00401-019-02037-5","volume":"138","author":"S Lohmann","year":"2019","unstructured":"Lohmann, S. et al. Oral and intravenous transmission of \u03b1-synuclein fibrils to mice. Acta Neuropathol 138, 515\u2013533 (2019).","journal-title":"Acta Neuropathol"},{"key":"690_CR34","doi-asserted-by":"publisher","unstructured":"Altendorf, T. et al. Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer\u2019s Disease and Other Tauopathies. Int J Mol Sci 24, https:\/\/doi.org\/10.3390\/ijms24032161 (2023).","DOI":"10.3390\/ijms24032161"},{"key":"690_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clinbiochem.2016.11.001","volume":"50","author":"Y Herrmann","year":"2017","unstructured":"Herrmann, Y. et al. sFIDA automation yields sub-femtomolar limit of detection for Abeta aggregates in body fluids. Clin Biochem 50, 244\u2013247 (2017).","journal-title":"Clin Biochem"},{"key":"690_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fneur.2015.00179","volume":"6","author":"U Andreasson","year":"2015","unstructured":"Andreasson, U. et al. A Practical Guide to Immunoassay Method Validation. Front Neurol 6, 179 (2015).","journal-title":"Front Neurol"},{"key":"690_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13195-017-0314-2","volume":"10","author":"F Jessen","year":"2018","unstructured":"Jessen, F. et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer\u2019s disease (DELCODE). Alzheimers Res Ther 10, 15 (2018).","journal-title":"Alzheimers Res Ther"},{"key":"690_CR38","doi-asserted-by":"publisher","unstructured":"Jessen, F. et al. Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimers Dement, https:\/\/doi.org\/10.1002\/alz.12674 (2022).","DOI":"10.1002\/alz.12674"},{"key":"690_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep 6, 26801 (2016).","journal-title":"Sci Rep"},{"key":"690_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/srep01302","volume":"3","author":"LA Miles","year":"2013","unstructured":"Miles, L. A., Crespi, G. A., Doughty, L. & Parker, M. W. Bapineuzumab captures the N-terminus of the Alzheimer\u2019s disease amyloid-beta peptide in a helical conformation. Sci Rep 3, 1302 (2013).","journal-title":"Sci Rep"},{"key":"690_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1515\/labmed-2018-0084","volume":"43","author":"MM Mohammadi","year":"2019","unstructured":"Mohammadi, M. M. & Bozorgi, S. Investigating the presence of human anti-mouse antibodies (HAMA) in the blood of laboratory animal care workers. Journal of Laboratory Medicine 43, 87\u201391 (2019).","journal-title":"Journal of Laboratory Medicine"},{"key":"690_CR42","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1002\/pmic.200500535","volume":"6","author":"S-Y Hsieh","year":"2006","unstructured":"Hsieh, S.-Y., Chen, R.-K., Pan, Y.-H. & Lee, H.-L. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum\/plasma proteome profiling. PROTEOMICS 6, 3189\u20133198 (2006).","journal-title":"PROTEOMICS"},{"key":"690_CR43","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1006\/bbrc.2000.2222","volume":"268","author":"YM Kuo","year":"2000","unstructured":"Kuo, Y. M. et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268, 750\u2013756 (2000).","journal-title":"Biochem Biophys Res Commun"},{"key":"690_CR44","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jalz.2017.01.010","volume":"13","author":"E Willemse","year":"2017","unstructured":"Willemse, E. et al. How to handle adsorption of cerebrospinal fluid amyloid \u03b2 (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A\u03b2(42)\/A\u03b2(40) ratio. Alzheimers Dement 13, 885\u2013892 (2017).","journal-title":"Alzheimers Dement"},{"key":"690_CR45","doi-asserted-by":"crossref","unstructured":"Bl\u00f6meke, L. et al. A\u03b2 oligomers peak in early stages of Alzheimer\u2019s disease preceding tau pathology. Alzheimers Dement (Amst 16, e12589 (2024). .","DOI":"10.1002\/dad2.12599"},{"key":"690_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","volume":"13","author":"M Gratuze","year":"2018","unstructured":"Gratuze, M., Leyns, C. E. G. & Holtzman, D. M. New insights into the role of TREM2 in Alzheimer\u2019s disease. Mol Neurodegener 13, 66 (2018).","journal-title":"Mol Neurodegener"},{"key":"690_CR47","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15, 501\u2013518 (2019).","journal-title":"Nat Rev Neurol"},{"key":"690_CR48","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/jaoac\/89.4.1095","volume":"89","author":"W Horwitz","year":"2006","unstructured":"Horwitz, W. & Albert, R. The Horwitz ratio (HorRat): A useful index of method performance with respect to precision. J AOAC Int 89, 1095\u20131109 (2006).","journal-title":"J AOAC Int"},{"key":"690_CR49","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13195-022-01104-6","volume":"14","author":"KY Kim","year":"2022","unstructured":"Kim, K. Y. et al. Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status. Alzheimer\u2019s Research & Therapy 14, 162 (2022).","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"690_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"F Jessen","year":"2020","unstructured":"Jessen, F. et al. The characterisation of subjective cognitive decline. Lancet Neurol 19, 271\u2013278 (2020).","journal-title":"Lancet Neurol"},{"key":"690_CR51","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement"},{"key":"690_CR52","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15, 673\u2013684 (2016).","journal-title":"Lancet Neurol"},{"key":"690_CR53","doi-asserted-by":"publisher","unstructured":"O\u2019Bryant, S. E., Petersen, M., Hall, J. & Johnson, L. A. Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: Important considerations for clinical trials and practice. Alzheimers Dement, https:\/\/doi.org\/10.1002\/alz.12647 (2022).","DOI":"10.1002\/alz.12647"},{"key":"690_CR54","doi-asserted-by":"crossref","unstructured":"Kutzsche, J. et al. Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study. Alzheimers Dement (N Y 6, e12001 (2020). .","DOI":"10.1002\/trc2.12001"},{"key":"690_CR55","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.neurobiolaging.2014.03.035","volume":"35","author":"BP Lucey","year":"2014","unstructured":"Lucey, B. P. & Bateman, R. J. Amyloid-\u03b2 diurnal pattern: possible role of sleep in Alzheimer\u2019s disease pathogenesis. Neurobiology of Aging 35, S29\u2013S34 (2014).","journal-title":"Neurobiology of Aging"},{"key":"690_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ana.25117","volume":"83","author":"BP Lucey","year":"2018","unstructured":"Lucey, B. P. et al. Effect of sleep on overnight cerebrospinal fluid amyloid \u03b2 kinetics. Ann Neurol 83, 197\u2013204 (2018).","journal-title":"Ann Neurol"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00690-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00690-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00690-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:04:32Z","timestamp":1733857472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-024-00690-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1038\/s43856-024-00690-w","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"3 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.W. and O.B. are co-founders and shareholders of attyloid GmbH. This affiliation had no influence of the interpretation of the data. All other authors declare no competing interests related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}